Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis

INTRODUCTION: We systematically assessed benefits and harms of tocilizumab (TCZ), which is an antibody blocking IL-6 receptors, in hospitalized COVID-19 patients. METHODS: Five electronic databases and two preprint webpages were searched until March 4, 2021. Randomized controlled trials (RCTs) and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Piscoya, Alejandro, Parra del Riego, Angela, Cerna-Viacava, Renato, Rocco, Jonathon, Roman, Yuani M., Escobedo, Angel A., Pasupuleti, Vinay, White, C. Michael, Hernandez, Adrian V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165853/
https://www.ncbi.nlm.nih.gov/pubmed/35657993
http://dx.doi.org/10.1371/journal.pone.0269368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165853/
https://www.ncbi.nlm.nih.gov/pubmed/35657993
http://dx.doi.org/10.1371/journal.pone.0269368

Ejemplares similares